Search Result

Pathways Recommended:	JAK/STAT Signaling

Results for "

selective JAK inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	JAK (182) Ack1 (1) Akt (7) AMPK (1) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (47) Aurora Kinase (2) Autophagy (12) Bacterial (3) Bcl-2 Family (1) BMX Kinase (1) Btk (1) c-Kit (1) c-Myc (1) Cadherin (1) Cannabinoid Receptor (1) Caspase (4) Cytochrome P450 (3) Deubiquitinase (3) DNA/RNA Synthesis (3) Drug Derivative (1) EGFR (5) ERK (1) Ferroptosis (1) FGFR (1) FLT3 (10) Glucocorticoid Receptor (1) GLUT (3) Glutathione Peroxidase (1) GSK-3 (4) HDAC (1) HIV (3) IFNAR (7) IGF-1R (1) IKK (2) Interleukin Related (19) IRAK (1) Isotope-Labeled Compounds (8) Itk (2) JNK (1) Ligands for Target Protein for PROTAC (1) LRRK2 (1) MAP4K (1) Microtubule/Tubulin (1) Mitophagy (4) Monoamine Oxidase (2) mTOR (3) NF-κB (4) NO Synthase (2) p38 MAPK (2) Phosphatase (2) PI3K (11) PKC (2) PROTACs (4) Protease Activated Receptor (PAR) (1) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (21) RET (4) ROCK (1) SGLT (3) Src (1) STAT (50) Syk (4) TAM Receptor (1) TNF Receptor (1) Trk Receptor (1) Tyrosinase (1) VEGFR (2)
By Research Areas:	Cancer (112) Cardiovascular Disease (5) Endocrinology (1) Infection (7) Inflammation/Immunology (99) Metabolic Disease (5) Neurological Disease (7)
Click Chemistry:	Alkynes (1)

204

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Targets Recommended: JAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50856

Ruxolitinib Maximum Cited Publications 259 Publications Verification INCB18424	JAK Autophagy Mitophagy Apoptosis	Cancer
Ruxolitinib (INCB18424) is an orally active and selective *JAK1/2* inhibitor with IC₅₀s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .

HY-15315

Baricitinib 70+ Cited Publications LY3009104; INCB028050	JAK	Inflammation/Immunology
Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable *JAK1* and *JAK2* inhibitor with IC₅₀s of 5.9 nM and 5.7 nM, respectively.

HY-19569

Upadacitinib 25+ Cited Publications ABT-494	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-10409

Fedratinib 50+ Cited Publications TG-101348; SAR 302503	JAK Apoptosis	Cancer
Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-50858

Ruxolitinib phosphate Maximum Cited Publications 259 Publications Verification INCB018424 phosphate	JAK Autophagy Mitophagy	Cancer
Ruxolitinib phosphate (INCB018424 phosphate) is a potent *JAK1/2* inhibitor with IC₅₀s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.

HY-18300

Filgotinib 20+ Cited Publications GLPG0634	JAK HIV	Cancer
Filgotinib (GLPG0634) is a selective, orally available *JAK1* inhibitor with anti-inflammatory and antiviral activities. Filgotinib can effectively inhibit the activities of *JAK1, JAK2, JAK3* and TYK2 with IC₅₀ values of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib can be used in the study of rheumatoid arthritis and inflammatory bowel disease .

HY-107361

Golidocitinib 2 Publications Verification AZD4205	JAK	Cancer
Golidocitinib (AZD4205) is a selective *JAK1* inhibitor, with an IC₅₀ of 73 nM, weakly inhibits JAK2 (IC₅₀>14.7 μM), and shows little inhibition on JAK3 (IC₅₀>30 μM) .

HY-15315A

Baricitinib phosphate 70+ Cited Publications LY3009104 phosphate; INCB028050 phosphate	JAK	Inflammation/Immunology
Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable *JAK1/JAK2* inhibitor with IC₅₀ of 5.9 nM and 5.7 nM, respectively.

HY-N1405

Cucurbitacin I 10+ Cited Publications Elatericin B; JSI-124; NSC-521777	STAT JAK	Cancer
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-15270

BMS-911543 4 Publications Verification	JAK	Cancer
BMS-911543 is a selective *JAK2* inhibitor, with IC₅₀s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 (IC₅₀, 75, 360, 66 nM, respectively).

HY-16997

Itacitinib 20+ Cited Publications INCB039110	JAK	Cancer
Itacitinib (INCB039110) is an orally active and selective inhibitor of *JAK1* with an IC₅₀ of 2 nM for human JAK1. Itacitinib shows >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis .

HY-10410

TG101209 5 Publications Verification	FLT3 JAK RET Autophagy Apoptosis	Cancer
TG101209 is a selective *JAK2* inhibitor with IC₅₀ of 6 nM, less potent to Flt3 and RET with IC₅₀ of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.

HY-10409A

Fedratinib hydrochloride hydrate 50+ Cited Publications TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate	JAK Apoptosis	Cancer
Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-112724

Ivarmacitinib SHR0302	JAK Apoptosis	Inflammation/Immunology Cancer
Ivarmacitinib (SHR0302) is a potent and orally active all members of the JAK family inhibitor, particularly *JAK1. The selectivity* of Ivarmacitinib for *JAK1* is >10-fold for *JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits* *JAK1-STAT3* phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .

HY-131906

JAK2-IN-7	JAK FLT3 Apoptosis	Cancer
JAK2-IN-7 is a selective *JAK2* inhibitor with IC₅₀s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 ^V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities .

HY-13775

XL019 5 Publications Verification	JAK Apoptosis	Cancer
XL019?is a potent, orally active, and selective *JAK2* inhibitor, with IC₅₀s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 .

HY-16755

Solcitinib 3 Publications Verification GSK-2586184; GLPG-0778	JAK	Inflammation/Immunology
Solcitinib is an orally active, competitive, potent, selective *JAK1* inhibitor, with an IC₅₀ of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.

HY-15999

Cerdulatinib 5+ Cited Publications PRT062070; PRT2070	JAK Syk	Cancer
Cerdulatinib (PRT062070) is a selective Tyk2 inhibitor with an IC₅₀ of 0.5 nM. Cerdulatinib (PRT062070) also is a dual *JAK* and SYK inhibitor with IC₅₀s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.

HY-101976

JAK3-IN-6	JAK	Inflammation/Immunology
JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC₅₀ of 0.15 nM.

HY-50856R

Ruxolitinib (Standard) INCB18424 (Standard)	Reference Standards JAK Autophagy Mitophagy Apoptosis	Cancer
Ruxolitinib (Standard) is the analytical standard of Ruxolitinib. This product is intended for research and analytical applications. Ruxolitinib (INCB18424) is a potent and selective *JAK1/2* inhibitor with IC₅₀s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .

HY-10962

Momelotinib sulfate 15+ Cited Publications CYT387 sulfate salt	JAK Autophagy Apoptosis	Cancer
Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀ of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC₅₀=155 nM).

HY-19631A

Ilginatinib 1 Publications Verification NS-018	JAK	Cancer
Ilginatinib (NS-018) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-120469

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide	JAK	Inflammation/Immunology
GDC-046 is a potent, selective, and orally bioavailable TYK2 inhibitor with K_is of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively .

HY-15315S

Baricitinib-d5 LY3009104-d₅; INCB028050-d₅	JAK	Inflammation/Immunology
Baricitinib-d₅ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-19631

Ilginatinib maleate 1 Publications Verification NS-018 maleate	JAK	Cancer
Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-19631B

Ilginatinib hydrochloride 1 Publications Verification NS-018 hydrochloride	JAK	Cancer
Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-108264

TCS 21311 NIBR3049	JAK PKC GSK-3	Cancer
TCS 21311 (NIBR3049) is a potent, highly selective *JAK3* inhibitor with an IC₅₀ of 8 nM, it displays >100-fold selectivity over JAK1, JAK2 and TYK2. TCS 21311 (NIBR3049) inhibits PKCα, PKCθ, and GSK3β with IC₅₀s of 13, 68, and 3 nM, respectively .

HY-102046

FM-381 2 Publications Verification	JAK	Inflammation/Immunology
FM-381, a chemical probe, is a potent covalent reversible inhibitor of *JAK3* targeting the unique Cys909. FM-381 has an IC₅₀ of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively .

HY-101024

PF-06263276	JAK STAT	Inflammation/Immunology
PF-06263276 (PF 6263276) is a potent and selective *pan-JAK* inhibitor, with IC₅₀s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively. PF-06263276 inhibits pSTAT3 and TYK2 pathway. PF-06263276 has a protective effect against ear skin inflammation .

HY-19544

JAK3-IN-1	JAK	Cancer
JAK3-IN-1 is a potent, selective and orally active *JAK3* inhibitor with an IC₅₀ of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for *JAK3* than JAK1 (IC₅₀ of 896 nM) and JAK2 (IC₅₀ of 1050 nM) .

HY-13827

JAK-IN-1 4 Publications Verification	JAK	Inflammation/Immunology
JAK-IN-1 is a *JAK1/2/3* inhibitor with IC₅₀s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.

HY-137756

JAK2-IN-6 1 Publications Verification	JAK	Cancer
JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective *JAK2* inhibitor with an IC₅₀ of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells .

HY-161684

JAK2-IN-10	JAK STAT	Cancer
JAK2-IN-10 is a selective JAK2 V617F inhibitor with an IC₅₀ value of ≤10 nM . JAK2-IN-10 can be used for the research of myeloproliferative neoplasms and other related diseases .

HY-175684

JAK2-IN-14	JAK STAT Apoptosis	Cancer
JAK2-IN-14 is an orally active *JAK2* inhibitor with an IC₅₀ of 2 nM. JAK2-IN-14 demonstrates 89.5-, 80.5-, and 51-fold selectivity over *JAK1, JAK3, and TYK2, respectively. JAK2-IN-14 inhibits* STAT5 signaling pathway. JAK2-IN-14 causes tumor cell cycle arrest and apoptosis. JAK2-IN-14 can used for the study of myeloproliferative neoplasms (MPNs) .

HY-152080

Blovacitinib TUL01101	JAK	Inflammation/Immunology
Blovacitinib (TUL01101) is a potent, selective and orally active *JAK1* inhibitor, with an IC₅₀s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Blovacitinib can be used for the research of rheumatoid arthritis .

HY-11067

WHI-P97 1 Publications Verification	JAK	Inflammation/Immunology
WHI-P97 is a potent and selective *JAK-3* inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo .

HY-124858

SC99	STAT JAK Apoptosis	Cardiovascular Disease Cancer
SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities .

HY-153568

JAK1-IN-11	JAK	Cancer
JAK1-IN-11 (compound 11) is a potent inhibitor of JAK，with IC₅₀s of 0.02 nM (JAK1)，and 0.44 nM (JAK2)，respectively. JAK1-IN-11 has high selectivity against JAK1 over JAK2 .

HY-116505

JAK1-IN-4	JAK	Cancer
JAK1-IN-4 is a potent and selective *JAK1* inhibitor, with IC₅₀s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC₅₀, 227 nM) .

HY-161015

JAK1-IN-13	JAK	Inflammation/Immunology
JAK1-IN-13 (compound 36b) is an orally active, potent and highly selective inhibitor of *JAK1* with an IC₅₀ of 0.044 nM. JAK1-IN-13 significantly decreases STAT3 phosphorylation .

HY-13450

ZM 449829	JAK EGFR	Inflammation/Immunology
ZM 449829 is a potent, selective and ATP competitive inhibitor of *JAK3, with a pIC₅₀* of 6.8. ZM 449829 will be useful pharmacological tools for the investigation of the *JAK3* .

HY-18300R

Filgotinib (Standard) GLPG0634 (Standard)	Reference Standards JAK	Cancer
Filgotinib (Standard) is the analytical standard of Filgotinib. This product is intended for research and analytical applications. Filgotinib (GLPG0634) is a selective and orally active *JAK1* inhibitor with IC₅₀ of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-100849

JAK 3i	JAK	Inflammation/Immunology
JAK3i is a highly selective *JAK3* inhibitor (IC₅₀: 0.43 nM). JAK3i forms a covalent bond with a cysteine in JAK3, but not the closely related kinase domains in JAK1, JAK2, or TYK2. JAK3i abolishes IL-2-driven T-cell proliferation in vivo and has the potential for autoimmune disease research .

HY-19569A

Upadacitinib tartrate tetrahydrate ABT-494 tartrate tetrahydrate	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research .

HY-148060

JAK-IN-21 1 Publications Verification	JAK	Cancer
JAK-IN-21 (Example 4) is a selective and potent *JAK* inhibitor with IC₅₀s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively .

HY-144440

JAK1-IN-9	JAK	Cancer
JAK1-IN-9 (compound 23a) is a potent and selective *JAK1* inhibitor with an IC₅₀ of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more .

HY-119935

JAK3 covalent inhibitor-1	JAK	Inflammation/Immunology
JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC₅₀ of 11 nM and shows 246-fold selectivity vs other JAKs .

HY-50859

Ruxolitinib sulfate INCB018424 sulfate	JAK Autophagy	Cancer
Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective *JAK1/2* inhibitor to enter the clinic with IC₅₀s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective *JAK2* inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .

HY-18300S

Filgotinib-d4 GLPG0634-d₄	JAK	Cancer
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

Cat. No.	Product Name	Type

HY-15244G

Alpelisib

Fluorescent Dyes

Alpelisib GMP is Alpelisib (HY-15244) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .

Cat. No.	Product Name	Type

HY-N0143A

Phlorizin dihydrate

10+ Cited Publications

Floridzin dihydrate

Biochemical Assay Reagents

Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC₅₀ of 0.04 μM and a K_i of 39 nM against hSGLT2, and an IC₅₀ of 0.17 μM and a K_i of 0.31 μM against hSGLT1. Phlorizin dihydrate promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities .

HY-15244G

Alpelisib

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0143

Phlorizin Maximum Cited Publications 15 Publications Verification Floridzin	Structural Classification Flavonoids Classification of Application Fields Malus pumila Mill. Rosaceae Phenols Polyphenols Metabolic Disease Plants Dihydrochalcones Disease Research Fields Source Classification	Caspase JAK GLUT STAT Apoptosis Bacterial SGLT mTOR Akt NF-κB PI3K DNA/RNA Synthesis
Phlorizin (Floridzin) is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC₅₀ of 0.04 μM and a K_i of 39 nM against hSGLT2, and an IC₅₀ of 0.17 μM and a K_i of 0.31 μM against hSGLT1. Phlorizin promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the *JAK/STAT3* and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities .

HY-N1405

Cucurbitacin I 10+ Cited Publications Elatericin B; JSI-124; NSC-521777	Triterpenes Classification of Application Fields Terpenoids Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-N0918

Desmethoxyyangonin Demethoxyyangonin; 5,6-Dehydrokavain	other families Classification of Application Fields Other Diseases Other Phenylpropanoids Phenylpropanoids Plants Disease Research Fields Source Classification	Monoamine Oxidase JAK IKK STAT NO Synthase Cytochrome P450
Desmethoxyyangonin is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin induces CYP3A23 expression and leads to skeletal muscle relaxation .

HY-125938

Cycloartenyl ferulate 1 Publications Verification Cycloartenol ferulate; Cycloartenol ferulic acid ester	Triterpenes Monophenols other families Classification of Application Fields Terpenoids Phenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Drug Derivative Apoptosis Reactive Oxygen Species (ROS) JAK STAT
Cycloartenyl ferulate (Cycloartenol ferulate; Cycloartenol ferulic acid ester) is a derivative of γ-oryzanol (HY-B2194) with multiple biological activities including antioxidant, anti-inflammatory, and anti-tumor properties. Cycloartenyl ferulate selectively binds to IFNγR1 (binding affinity K_d = 0.5 μM) to activate the canonical *JAK1/2-STAT1* signaling pathway. Cycloartenyl ferulate inhibits paraquat (PQ)-triggered apoptosis and ROS in HK2 cells. Cycloartenyl ferulate enhances the activation and cytolytic activity of natural killer (NK) cells by upregulating the expression of NK cell activation receptors (NKG2D, NKp30, NKp44) and the release of cytotoxic molecules and cytokine IFNγ. Cycloartenyl ferulate exerts anti-cancer effects in tumor mice models. Cycloartenyl ferulate can be used for the study of cancer and allergic inflammation intervention .

HY-N1405R

Cucurbitacin I (Standard) Elatericin B (Standard); JSI-124 (Standard); NSC-521777 (Standard)	Triterpenes Structural Classification Classification of Application Fields Terpenoids Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Source Classification Cancer	STAT JAK Reference Standards
Cucurbitacin I (Standard) is the analytical standard of Cucurbitacin I. This product is intended for research and analytical applications. Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-N0918R

Desmethoxyyangonin (Standard) Demethoxyyangonin (Standard); 5,6-Dehydrokavain (Standard)	Structural Classification other families Other Phenylpropanoids Phenylpropanoids Plants Source Classification	Reference Standards Monoamine Oxidase JAK STAT NO Synthase IKK Cytochrome P450
Desmethoxyyangonin (Standard) is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin (Standard) is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin (Standard) exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin (Standard) induces CYP3A23 expression and leads to skeletal muscle relaxation .

HY-N0143R

Phlorizin (Standard) Floridzin (Standard)	Structural Classification Flavonoids Malus pumila Mill. Rosaceae Phenols Polyphenols Plants Dihydrochalcones Source Classification	Reference Standards Caspase JAK GLUT STAT Apoptosis Bacterial SGLT mTOR Akt NF-κB PI3K DNA/RNA Synthesis
Phlorizin (Floridzin) (Standard) is the analytical standard of Phlorizin. This product is intended for research and analytical applications. Phlorizin is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC₅₀ of 0.04 μM and a K_i of 39 nM against hSGLT2, and an IC₅₀ of 0.17 μM and a K_i of 0.31 μM against hSGLT1. Phlorizin promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the *JAK/STAT3* and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities .

HY-N14094

Tubulosine	Structural Classification Alkaloids Other Alkaloids Rubiaceae Plants Pogonopus tubulosus (A.Rich. ex DC.) K.Schum. Source Classification	JAK Apoptosis Autophagy
Tubulosine is an alkaloid. Tubulosine can be isolated from Pogonopus tubulosus (DC.) Schumann. Tubulosine is an ATP-competitive, selective *JAK3* inhibitor with an IC₅₀ value of 9.9 nM. Tubulosine also inhibits the kinase activities of other JAK family members, the extent of inhibition is less than that of JAK3, with IC₅₀ values of 69.5, 84.9 and 76.3 nM for JAK1, JAK2 and TYK2, respectively. Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3. Tubulosine induces apoptotic and necrotic/autophagic cell death. Tubulosine inhibits the process of peptide chain elongation by eukaryotic polysomes by, specifically preventing the elongation-factor-2-dependent step of translocation. Tubulosine exhibits anticancer activity in breast cancer cells .

Cat. No.	Product Name	Chemical Structure

HY-117287

Deucravacitinib

Maximum Cited Publications

33 Publications Verification

Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC₅₀ of 0.2 nM and a K_i of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .

HY-131968

BMS-986202

1 Publications Verification

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-15315S

Baricitinib-d5
Baricitinib-d₅ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-153701S

Envudeucitinibum

Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

HY-161684

JAK2-IN-10
JAK2-IN-10 is a selective JAK2 V617F inhibitor with an IC₅₀ value of ≤10 nM . JAK2-IN-10 can be used for the research of myeloproliferative neoplasms and other related diseases .

HY-W727879

Upadacitinib-15N,d2

1 Publications Verification

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

HY-19569S1

Upadacitinib-d5

Upadacitinib-d₅ (ABT-494-d₅) is the deuterium labeled Upadacitinib (HY-19569). Upadacitinib (ABT-494) is a potent, orally active and selective JAK1 inhibitor (IC₅₀ = 43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-18300S

Filgotinib-d4
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-144031S

Tyk2-IN-8
Tyk2-IN-8 (compound 3) is a selective Tyk-2 inhibitor with an IC₅₀ of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC₅₀ of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease .

HY-50856S2

Ruxolitinib-d9
Ruxolitinib-d₉ (INCB18424-d₉) is deuterium labeled Ruxolitinib. Ruxolitinib (INCB18424) is an orally active and selective *JAK1/2* inhibitor with IC₅₀s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .

HY-15315S1

Baricitinib-d3
Baricitinib-d₃ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-10409S

Fedratinib-d9

Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-169984S

Tyk2-IN-22-d3
Tyk2-IN-22-d3 (Compound 1) is the deuterated analog of Tyk2-IN-22 (HY-168339). Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits Tyk2, *JAK1, and JAK3* with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation .

HY-145588S

Povorcitinib-d6
Povorcitinib-d₆ (INCB54707-d₆) is the deuterium labeled Povorcitinib (HY-145588). Povorcitinib (INCB54707) is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib is used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) .

Cat. No.	Product Name		Classification

HY-U00318

JAK-IN-11		Alkynes
JAK-IN-11 (Example 1,II) is a potent and selective *JAK* inhibitor. JAK-IN-11 has the potential for the skin disorders (such as cutaneous lupus) treatment . JAK-IN-11 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Targets Recommended: JAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15244G

Alpelisib	PI3K Apoptosis	Cancer
Alpelisib GMP is Alpelisib (HY-15244) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and *JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits* the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

selective JAK inhibitor

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Natural
Products